Stock DXR DAXOR CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

News Daxor Corporation Nyse

Equities

DXR

US2394671034

Delayed Nyse
Other stock markets
 10:06:12 2024-04-26 am EDT 		5-day change 1st Jan Change
9.65 USD 0.00% Intraday chart for Daxor Corporation -0.92% +0.52%
Apr. 16 Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor?s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion CI
Apr. 10 Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
AQ
Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor?s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
CI
Daxor Corporation to Exhibit at the Medaxiom Cardiovascular Transforum Conference Spring'24 to Advance Awareness and Further Adoption of Daxor's Blood Volume Diagnostic
AQ
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)
AQ
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital
AQ
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital
CI
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24
AQ
Transcript : Daxor Corporation, 2023 Earnings Call, Mar 25, 2024
Daxor to Acquire Volumex, Megatope to Increase Diagnostics Suite
MT
Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics
AQ
Daxor Corporation has entered into a definitive agreement to acquire Volumex®, Megatope® and Glofil® from Iso-Tex Diagnostics, Inc.
CI
Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024
AQ
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
AQ
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
AQ
Daxor Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base
AQ
Daxor Corporation Announces Sales to Three New Hospitals Furthering Expansion of Its User Base
CI
Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients
AQ
Daxor Corporation Announces New Data from Duke University Medical Center Validating the Benefits of Blood Volume Analysis
CI
Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DXR Stock
  4. DXR Stock
  5. News Daxor Corporation